NCT04260698 - Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

May 8, 2025

Study Completion Date

May 8, 2025

Conditions

Hematological Malignancies

Interventions

BIOLOGICAL

omidubicel

hematopoietic stem cell transplant

Trial Locations (6)

Duke University Medical Center, Durham

University of Minnesota Masonic Cancer Center, Minneapolis

Loyola University, Cardinal Bernardin Cancer Center, Maywood

UCLA, Los Angeles

Stanford University Cancer Institute, Palo Alto

Oregon Health & Science University, Portland